Iris atrophy after administration of Dexycu: Additional evidence and possible mechanism for a rare complication.

PURPOSE: To report the observation of iris atrophy with the use of Dexycu in cataract surgery and describe a possible mechanism for this complication.

OBSERVATIONS: Between 2020 and 2021, 2 patients underwent cataract surgery procedures with the use of Dexycu and experienced iris atrophy. The first case of iris atrophy was discovered by 6-month follow-up and the second case by 2-month follow-up. The timing and nature of this complication possibly represent more than steroid-induced hypopigmentation.

CONCLUSIONS AND

IMPORTANCE

This publication adds further evidence of iris atrophy and a proposed mechanism associated with the use of Dexycu. Surgeons should be aware of this complication, especially when operating on eyes with dark irides.